Cargando…
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. F...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350600/ https://www.ncbi.nlm.nih.gov/pubmed/32646443 http://dx.doi.org/10.1186/s13014-020-01595-3 |
_version_ | 1783557300418510848 |
---|---|
author | Käsmann, Lukas Eze, Chukwuka Taugner, Julian Roengvoraphoj, Olarn Dantes, Maurice Schmidt-Hegemann, Nina-Sophie Schiopu, Sanziana Belka, Claus Manapov, Farkhad |
author_facet | Käsmann, Lukas Eze, Chukwuka Taugner, Julian Roengvoraphoj, Olarn Dantes, Maurice Schmidt-Hegemann, Nina-Sophie Schiopu, Sanziana Belka, Claus Manapov, Farkhad |
author_sort | Käsmann, Lukas |
collection | PubMed |
description | Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC. |
format | Online Article Text |
id | pubmed-7350600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73506002020-07-14 Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy Käsmann, Lukas Eze, Chukwuka Taugner, Julian Roengvoraphoj, Olarn Dantes, Maurice Schmidt-Hegemann, Nina-Sophie Schiopu, Sanziana Belka, Claus Manapov, Farkhad Radiat Oncol Review Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC. BioMed Central 2020-07-09 /pmc/articles/PMC7350600/ /pubmed/32646443 http://dx.doi.org/10.1186/s13014-020-01595-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Käsmann, Lukas Eze, Chukwuka Taugner, Julian Roengvoraphoj, Olarn Dantes, Maurice Schmidt-Hegemann, Nina-Sophie Schiopu, Sanziana Belka, Claus Manapov, Farkhad Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
title | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
title_full | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
title_fullStr | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
title_full_unstemmed | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
title_short | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
title_sort | chemoradioimmunotherapy of inoperable stage iii non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350600/ https://www.ncbi.nlm.nih.gov/pubmed/32646443 http://dx.doi.org/10.1186/s13014-020-01595-3 |
work_keys_str_mv | AT kasmannlukas chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT ezechukwuka chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT taugnerjulian chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT roengvoraphojolarn chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT dantesmaurice chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT schmidthegemannninasophie chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT schiopusanziana chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT belkaclaus chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT manapovfarkhad chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy |